EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 40 / Numéro 6-7 (Juin-Juillet 2024) Med Sci (Paris), 40 6-7 (2024) 525-533 Références
Open Access
Numéro
Med Sci (Paris)
Volume 40, Numéro 6-7, Juin-Juillet 2024
Page(s) 525 - 533
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2024079
Publié en ligne 8 juillet 2024
  1. Pitard B.. Nanotaxi® pour les vaccins ARN et ADN. Med Sci (Paris) 2019 ; 35 : 749–752. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Rohner E, Yang R, Foo KS, et al. Unlocking the promise of mRNA therapeutics. Nat Biotechnol 2022; 40 : 1 586–600. [Google Scholar]
  3. Gupta A, Andresen JL, Manan RS, Langer R. Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev 2021; 178 : 113 834. [Google Scholar]
  4. Labs R, Beilvert F, Barteau B, et al. Nature as a source of inspiration for cationic lipid synthesis. Genetica 2010 ; 138 : 153–168. [CrossRef] [PubMed] [Google Scholar]
  5. Pitard B, Aguerre O, Airiau M, et al. Virus-sized self-assembling lamellar complexes between plasmid DNA and cationic micelles promote gene transfer. Proc Natl Acad Sci USA 1997 ; 94 : 14412–417. [CrossRef] [PubMed] [Google Scholar]
  6. Pitard B, Habrant D. Supramolecular Gene Transfection Agents. In: Jerry L. Atwood. Comprehensive Supramolecular Chemistry II. Amsterdam, Netherlands: Elsevier, 2017 : pp. 365–389. [CrossRef] [Google Scholar]
  7. Jones CH, Androsavich JR, So N, et al. Breaking the mod with RNA – a “RNaissance” of life science. NPJ Genom Med 2024; 9 : 2. [Google Scholar]
  8. Desigaux L, Sainlos M, Lambert O, et al. Self-assembled lamellar complexes of siRNA with lipidic aminoglycoside derivatives promote efficient siRNA delivery and interference. Proc Natl Acad Sci USA 2007 ; 104 : 16 534–539. [Google Scholar]
  9. Colombani T, Peuziat P, Dallet L, et al. Self-assembling complexes binary mixtures of lipids with different linkers and nucleic acids promote universal mRNA, DNA and siRNA delivery. J Control Release 2017 ; 249 : 131–142. [CrossRef] [PubMed] [Google Scholar]
  10. Habrant D, Peuziat P, Colombani T, et al. Design of ionizable lipids to overcome the limiting step of endosomal escape : application in the intracellular delivery of mRNA. DNA and siRNA. J Med Chem 2016 ; 59 : 3 046–062. [Google Scholar]
  11. Blanchard E, Loomis KH, Bhosle SM, et al. Proximity Ligation Assays for In Situ Detection of Innate Immune Activation : Focus on In Vitro-Transcribed mRNA. Mol Ther Nucleic Acids 2019 ; 14 : 52–66. [CrossRef] [PubMed] [Google Scholar]
  12. Bhosle SM, Loomis KH, Kirschman JL, et al. Unifying in vitro and in vivo IVT mRNA expression discrepancies in skeletal muscle via mechanotransduction. Biomaterials 2018 ; 159 : 189–203. [CrossRef] [PubMed] [Google Scholar]
  13. Lindsay KE, Bhosle SM, Zurla C, et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging. Nat Biomed Eng 2019 ; 3 : 371–380. [CrossRef] [PubMed] [Google Scholar]
  14. Le Bihan O, Chèvre R, Mornet S, et al. Probing the in vitro mechanism of action of cationic lipid/DNA lipoplexes at a nanometric scale. Nucleic Acids Res 2011 ; 39 : 1 595–609. [Google Scholar]
  15. Hou X, Zaks T, Langer R and Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater 2021; 6 : 1 078–94. [Google Scholar]
  16. Colombani T, Haudebourg T, Decossas M, et al. Lipidic Aminoglycoside Derivatives : A New Class of Immunomodulators Inducing a Potent Innate Immune Stimulation. Adv Sci (Weinh) 2019; 6 : 1 900 288. [CrossRef] [Google Scholar]
  17. Alameh MG, Tombácz I, Bettini E, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 2021; 54 : 2 877–92. [Google Scholar]
  18. Ndeupen S, Qin Z, Jacobsen S, et al. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 2021; 24 : 103 479. [Google Scholar]
  19. Barmada A, Klein J, Ramaswamy A, et al. Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine-associated myocarditis. Sci Immunol 2023; 8 : eadh3455. [CrossRef] [PubMed] [Google Scholar]
  20. Pitard B, Bello-Roufaï M, Lambert O, et al. Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. Nucleic Acids Res 2004 ; 16 : e159. [Google Scholar]
  21. Pitard B. Capped and uncapped RNA molecules and Block copolymers for intracellular delivery of RNA. Patent 2022 : US20220105203A1. [Google Scholar]
  22. Chèvre R, Le Bihan O, Beilvert F, et al. Amphiphilic block copolymers enhance the cellular uptake of DNA molecules through a facilitated plasma membrane transport. Nucleic Acids Res 2011 ; 39 : 1610–622. [Google Scholar]
  23. Colombani T, Haudebourg T, Pitard B. 704/DNA vaccines leverage cytoplasmic DNA stimulation to promote anti-HIV neutralizing antibody production in mice and strong immune response against alpha-fetoprotein in non-human primates. Mol Ther Nucleic Acids 2023; 32 : 743–57. [CrossRef] [PubMed] [Google Scholar]
  24. Verbeke R, Hogan ML, Loré K, Pardi N. Innate immune mechanisms of mRNA vaccines. Immunity 2022; 55 : 1993–2005. [CrossRef] [PubMed] [Google Scholar]
  25. Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors : the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005 ; 23 : 165–175. [CrossRef] [PubMed] [Google Scholar]
  26. Barbier AJ, Jiang AY, Zhang P, et al. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol 2022; 40 : 840–54. [CrossRef] [PubMed] [Google Scholar]
  27. Liu S, Cheng Q, Wei T, et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing. Nat Mater 2021; 20 : 701–10. [CrossRef] [PubMed] [Google Scholar]
  28. Anttila V, Saraste A, Knuuti J, et al. Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting. Mol Ther 2023; 31 : 866–74. [CrossRef] [PubMed] [Google Scholar]
  29. Rowe SM, Zuckerman JB, Dorgan D et al. Inhaled mRNA therapy for treatment of cystic fibrosis : Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study. J Cys Fibros 2023; 22 : 656–64. [CrossRef] [Google Scholar]
  30. Jiang AY, Witten J, Raji IO, et al. Combinatorial development of nebulized mRNA delivery formulations for the lungs. Nat Nanotechnol 2024; 19 : 364–75. [CrossRef] [PubMed] [Google Scholar]
  31. Seker Yilmaz B, Gissen P. Genetic Therapy Approaches for Ornithine Transcarbamylase Deficiency. Biomedicines. 2023; 8 : 2 227. [Google Scholar]
  32. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater 2021; 6 : 1 078–94. [Google Scholar]
  33. Attarwala H, Lumley M, Liang M, et al. Translational Pharmacokinetic/Pharmacodynamic Model for mRNA-3927, an Investigational Therapeutic for the Treatment of Propionic Acidemia. Nucleic Acid Ther 2023; 33 : 141–7. [Google Scholar]
  34. Koeberl D, Schulze A, Sondheimer N, et al. Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia. Nature 2024; 628 : 872–7. [CrossRef] [PubMed] [Google Scholar]
  35. Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med 2021; 385 : 493–502. [CrossRef] [PubMed] [Google Scholar]
  36. August A, Attarwala HZ, Himansu S, et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat Med 2021; 27 : 2 224–33. [Google Scholar]
  37. BioNtech website. BioNtech mRNA pipeline. BNT153&BNT152: RiboCytokines IL-2 and IL-7 in various solid tumors. https://www.biontech.com/int/en/home/pipeline-and-products/pipeline.html#bnt411-solid-tumors. [Google Scholar]
  38. Moderna website. Moderna mRNA pipeline. mRNA-2752: OX40/IL-23/IL-36g (Triplet)/solid tumors/lymphoma. https://www.modernatx.com/research/product-pipeline. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.